Grading of breast cancer
OwnerMark G. Erlander, Xiao-Jun Ma +1inventors
InventorsMark G. Erlander, Xiao-Jun Ma, Dennis C. Sgroi
Life of this patent
Estimating the term…
Abstract
Methods and compositions for the identification of breast cancer grade signatures are provided. The signature profiles are identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for identification of cells as being in one or more particular stages and/or grades of breast cancer.
Claims104
An array comprising polynucleotide probes, capable of hybridizing to nucleic acid molecules of more than one of the genes listed in Table 2, hybridized to nucleic acids derived from a cell suspected of being non-normal.
An array comprising polynucleotide probes, capable of hybridizing to nucleic acid molecules of more than one of the genes in Table 3, hybridized to nucleic acids derived from a cell suspected of being DCIS or IDC.
An array comprising polynucleotide probes, capable of hybridizing to nucleic acid molecules of more than one of the genes in Table 4, hybridized to nucleic acids derived from a cell suspected of being non-normal.
A method to determine the presence, grade or stage of breast cancer cells in a sample from a subject comprising assaying said sample for expression of one or more genes in Table 2 and/or one or more genes in Table 4.
A method to determine the presence, grade or stage of breast cancer cells in a sample from a subject comprising
- assaying said sample for expression of one or more genes selected from Table 2 and/or Table 4 and
- identifying said sample as containing non-normal breast cancer cells, optionally without grading by histomorphological criteria.
A method to determine the presence of DCIS and/or IDC breast cancer cells of grade III in a sample from a subject comprising
- assaying said sample for expression of one or more genes selected from Table 3, Table 6, and/or Table 9 and
- identifying said sample as containing breast cancer cells of grade III, optionally without grading by histomorphological criteria.
A method to determine the grade of either DCIS or IDC cancer progression in a sample from a subject comprising assaying said sample for expression of one or more genes listed in Table 10.
A method to determine the presence of DCIS and/or IDC breast cancer cells of grade I in a sample from a subject comprising
- assaying said sample for expression of one or more genes selected from Table 7 and/or Table 8 and
- identifying said sample as containing breast cancer cells of grade I, optionally without grading by histomorphological criteria.
A method to determine the presence of DCIS and/or IDC breast cancer cells of grade I and/or grade III in a sample from a subject comprising assaying said sample for decreased expression of one or more genes selected from Table 5.
An array comprising polynucleotide probes, capable of hybridizing to nucleic acid molecules of more than one of the genes listed in Table 5, hybridized to nucleic acids derived from a cell suspected of being DCIS or IDC.
An array comprising polynucleotide probes, capable of hybridizing to nucleic acid molecules of more than one of the genes listed in Table 6 and/or Table 9, hybridized to nucleic acids derived from a cell suspected of being grade III DCIS and/or IDC.
An array comprising polynucleotide probes, capable of hybridizing to nucleic acid molecules of more than one of the genes listed in Table 7 and/or Table 8, hybridized to nucleic acids derived from a cell suspected of being grade I DCIS and/or IDC.
An array comprising polynucleotide probes, capable of hybridizing to nucleic acid molecules of more than one of the genes listed in Table 10, hybridized to nucleic acids derived from a cell suspected of being DCIS or IDC.
A method to determine therapeutic treatment for a patient having cells suspected of being non-normal in a sample therefrom comprising
- identifying said patient as having grade III DCIS and/or IDC after assaying said cells for expression of more than one gene listed in Table 3 and
- selecting the appropriate treatment for a patient having cells of such a grade.
A method to determine therapeutic treatment for a patient having non-normal cells in a sample therefrom comprising
- identifying said patient as having grade III DCIS and/or IDC after assaying said cells for expression of more than one gene listed in Table 6 and/or Table 9, and
- selecting the appropriate treatment for a patient having cells of such a grade.
A method to determine therapeutic treatment for a patient having non-normal cells in a sample therefrom comprising
- identifying said patient as having grade I DCIS and/or IDC after assaying said cells for expression of more than one gene listed in Table 7 and/or Table 8, and
- selecting the appropriate treatment for a patient having cells of such a grade.
Dependencies are inferred from the claim text.